EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

Goadsby, PDodick, DSpierings, EScherer, JSweeney, SGrayzel, D2014-11-032014Goadsby, P, D Dodick, E Spierings, J Scherer, S Sweeney, and D Grayzel. 2014. “EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study.” The Journal of Headache and Pain 15 (Suppl 1): G10. doi:10.1186/1129-2377-15-S1-G10. http://dx.doi.org/10.1186/1129-2377-15-S1-G10.1129-2369http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347502en-USEHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled studyJournal Article2014-11-0310.1186/1129-2377-15-S1-G10